Olverembatinib [CAS 1257628-77-5]

Olverembatinib (GZD824) is a potent and orally active pan-Bcr-Abl inhibitor. Olverembatinib potently inhibits a broad spectrum of Bcr-Abl mutants. Olverembatinib strongly inhibits native Bcr-Abl and Bcr-AblT315I with IC50s of 0.34 nM and 0.68 nM, respectively. Olverembatinib has antitumor activity[1]. Olverembatinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

[1257628-77-5]

C29H27F3N6O

532.56

O=C(NC1=CC=C(CN2CCN(C)CC2)C(C(F)(F)F)=C1)C3=CC=C(C)C(C#CC4=CN=C(NN=C5)C5=C4)=C3

Bcr-Abl

10mM

99.47

DMSO : 41.67 mg/mL (ultrasonic; warming; heat to 60°C)

-20°C, 3 years; 4°C, 2 years (Powder)

Room Temperature

H302

H302